Johnson Chemical Pharmaceutical Works Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Johnson Chemical Pharmaceutical Works heeft een totaal eigen vermogen van NT$1.7B en een totale schuld van NT$149.7M, wat de schuld-eigenvermogensverhouding op 8.9% brengt. De totale activa en totale passiva bedragen respectievelijk NT$1.9B en NT$261.5M. De EBIT Johnson Chemical Pharmaceutical Works is NT$96.7M waardoor de rentedekking -9.5 is. Het heeft contanten en kortetermijnbeleggingen van NT$1.1B.

Belangrijke informatie

8.9%

Verhouding schuld/eigen vermogen

NT$149.73m

Schuld

Rente dekkingsratio	-9.5x
Contant	NT$1.05b
Aandelen	NT$1.68b
Totaal verplichtingen	NT$261.50m
Totaal activa	NT$1.95b

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Feb 18

Recent updates

Could Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Have The Makings Of Another Dividend Aristocrat?

Mar 25

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Feb 18

Weak Financial Prospects Seem To Be Dragging Down Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Stock

Feb 01

Estimating The Fair Value Of Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747)

Jan 12

Is Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) An Attractive Dividend Stock?

Dec 25

Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Growing Earnings But Are They A Good Guide?

Dec 07

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$1.3B ) 4747 } overtreffen de korte termijn passiva ( NT$171.8M ).

Langlopende schulden: De kortetermijnactiva 4747 ( NT$1.3B ) overtreffen de langetermijnschulden ( NT$89.7M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 4747 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 4747 is de afgelopen 5 jaar gestegen van 0% naar 8.9%.

Schuldendekking: De schuld van 4747 wordt goed gedekt door de operationele kasstroom ( 55.6% ).

Rentedekking: 4747 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Johnson Chemical Pharmaceutical Works Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.47 (vs NT$0.46 in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$0.50 (vs NT$0.75 in 2Q 2023)

Now 20% overvalued

Upcoming dividend of NT$1.50 per share

First quarter 2024 earnings released: EPS: NT$0.45 (vs NT$0.74 in 1Q 2023)

Full year 2023 earnings released: EPS: NT$2.24 (vs NT$2.16 in FY 2022)

New minor risk - Market cap size

Johnson Chemical Pharmaceutical Works Co., Ltd., Annual General Meeting, May 24, 2024

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: NT$0.45 (vs NT$0.64 in 3Q 2022)

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: EPS: NT$0.75 (vs NT$0.48 in 2Q 2022)

New minor risk - Market cap size

Investor sentiment improves as stock rises 26%

Upcoming dividend of NT$2.00 per share at 2.5% yield

Investor sentiment improves as stock rises 17%

First quarter 2023 earnings released: EPS: NT$0.75 (vs NT$0.42 in 1Q 2022)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: NT$2.16 (vs NT$1.64 in FY 2021)

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

No independent directors

Third quarter 2022 earnings released: EPS: NT$0.64 (vs NT$0.44 in 3Q 2021)

Second quarter 2022 earnings released: EPS: NT$0.48 (vs NT$0.43 in 2Q 2021)

Upcoming dividend of NT$1.45 per share

First quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.35 in 1Q 2021)

No independent directors

Full year 2021 earnings released: EPS: NT$1.64 (vs NT$2.12 in FY 2020)

Johnson Chemical Pharmaceutical Works Co., Ltd., Annual General Meeting, May 26, 2022

Third quarter 2021 earnings released: EPS NT$0.44 (vs NT$0.47 in 3Q 2020)

Upcoming dividend of NT$1.92 per share

First quarter 2021 earnings released: EPS NT$0.35 (vs NT$0.61 in 1Q 2020)

Could Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Have The Makings Of Another Dividend Aristocrat?

Full year 2020 earnings released: EPS NT$2.12 (vs NT$2.15 in FY 2019)

New 90-day high: NT$37.65

Johnson Chemical Pharmaceutical Works Co., Ltd., Annual General Meeting, May 17, 2021

These 4 Measures Indicate That Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Using Debt Reasonably Well

Weak Financial Prospects Seem To Be Dragging Down Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) Stock

New 90-day low: NT$36.80

Estimating The Fair Value Of Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747)

Is Johnson Chemical Pharmaceutical Works Co., Ltd. (GTSM:4747) An Attractive Dividend Stock?

Johnson Chemical Pharmaceutical Works (GTSM:4747) Is Growing Earnings But Are They A Good Guide?

Third quarter 2020 earnings released: EPS NT$0.47

New 90-day low - NT$37.55

New 90-day low - NT$38.10

First half earnings released

New 90-day low - NT$39.00

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven